Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Karolinska Development AB ( (SE:KDEV) ) has shared an announcement.
Karolinska Development’s portfolio company, BOOST Pharma, has announced promising long-term results from its BOOSTB4 phase 1/2 trial for BT-101, a cell-based therapy targeting Osteogenesis imperfecta. The data, presented at an international conference, shows a significant reduction in bone fractures among treated patients, indicating BT-101’s potential as a disease-modifying treatment in an area with high medical need and no adequate existing treatments.
More about Karolinska Development AB
Karolinska Development AB is a Nordic life sciences investment company focused on identifying breakthrough medical innovations in the Nordic region. The company invests in developing these innovations into commercial products that aim to improve patients’ lives and provide attractive returns to shareholders. With access to world-class medical innovations at the Karolinska Institutet and other leading research institutes, Karolinska Development supports the growth of companies targeting innovative treatments for life-threatening or serious debilitating diseases.
Average Trading Volume: 284,420
Current Market Cap: SEK233.9M
For detailed information about KDEV stock, go to TipRanks’ Stock Analysis page.